CYTOF
Price
$0.15
Change
+$0.05 (+50.00%)
Updated
Jan 12 closing price
Capitalization
837.32K
Intraday BUY SELL Signals
SPHDF
Price
$13.35
Change
+$1.08 (+8.80%)
Updated
Nov 13 closing price
Capitalization
233M
Intraday BUY SELL Signals
Interact to see
Advertisement

CYTOF vs SPHDF

Header iconCYTOF vs SPHDF Comparison
Open Charts CYTOF vs SPHDFBanner chart's image
Altamira Therapeutics
Price$0.15
Change+$0.05 (+50.00%)
Volume$20.38K
Capitalization837.32K
Santhera Pharmaceuticals Holdings
Price$13.35
Change+$1.08 (+8.80%)
Volume$200
Capitalization233M
CYTOF vs SPHDF Comparison Chart in %
CYTOF
Daily Signal:
Gain/Loss:
SPHDF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CYTOF vs. SPHDF commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTOF is a Hold and SPHDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (CYTOF: $0.15 vs. SPHDF: $13.35)
Brand notoriety: CYTOF and SPHDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTOF: 209% vs. SPHDF: 94%
Market capitalization -- CYTOF: $837.32K vs. SPHDF: $233M
CYTOF [@Biotechnology] is valued at $837.32K. SPHDF’s [@Biotechnology] market capitalization is $233M. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTOF’s FA Score shows that 1 FA rating(s) are green whileSPHDF’s FA Score has 1 green FA rating(s).

  • CYTOF’s FA Score: 1 green, 4 red.
  • SPHDF’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTOF is a better buy in the long-term than SPHDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTOF’s TA Score shows that 6 TA indicator(s) are bullish while SPHDF’s TA Score has 2 bullish TA indicator(s).

  • CYTOF’s TA Score: 6 bullish, 4 bearish.
  • SPHDF’s TA Score: 2 bullish, 0 bearish.
According to our system of comparison, CYTOF is a better buy in the short-term than SPHDF.

Price Growth

CYTOF (@Biotechnology) experienced а +46.50% price change this week, while SPHDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPHDF($233M) has a higher market cap than CYTOF($837K). SPHDF has higher P/E ratio than CYTOF: SPHDF (2.53) vs CYTOF (0.05). CYTOF YTD gains are higher at: 58.396 vs. SPHDF (0.000).
CYTOFSPHDFCYTOF / SPHDF
Capitalization837K233M0%
EBITDA-5.46MN/A-
Gain YTD58.3960.000-
P/E Ratio0.052.532%
Revenue0N/A-
Total Cash3.76KN/A-
Total Debt790KN/A-
FUNDAMENTALS RATINGS
CYTOF vs SPHDF: Fundamental Ratings
CYTOF
SPHDF
OUTLOOK RATING
1..100
3242
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3661
P/E GROWTH RATING
1..100
10012
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYTOF's Valuation (7) in the Biotechnology industry is somewhat better than the same rating for SPHDF (54) in the null industry. This means that CYTOF’s stock grew somewhat faster than SPHDF’s over the last 12 months.

CYTOF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SPHDF (100) in the null industry. This means that CYTOF’s stock grew similarly to SPHDF’s over the last 12 months.

CYTOF's SMR Rating (99) in the Biotechnology industry is in the same range as SPHDF (100) in the null industry. This means that CYTOF’s stock grew similarly to SPHDF’s over the last 12 months.

CYTOF's Price Growth Rating (36) in the Biotechnology industry is in the same range as SPHDF (61) in the null industry. This means that CYTOF’s stock grew similarly to SPHDF’s over the last 12 months.

SPHDF's P/E Growth Rating (12) in the null industry is significantly better than the same rating for CYTOF (100) in the Biotechnology industry. This means that SPHDF’s stock grew significantly faster than CYTOF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTOFSPHDF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
12%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
11%
Advances
ODDS (%)
Bullish Trend 13 days ago
83%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CYTOF
Daily Signal:
Gain/Loss:
SPHDF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTTEX15.73N/A
N/A
Fidelity Advisor Total Intl Equity M
FBIOX24.84N/A
N/A
Fidelity Select Biotechnology
CCMAX9.36N/A
N/A
Conestoga Mid Cap Institutional
ABCEX10.64-0.03
-0.28%
AB Emerging Markets Multi-Asset C
SVOAX13.26-0.05
-0.38%
SEI US Managed Volatility F (SIMT)

CYTOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTOF has been loosely correlated with CMND. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTOF jumps, then CMND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTOF
1D Price
Change %
CYTOF100%
N/A
CMND - CYTOF
56%
Loosely correlated
+12.96%
COGT - CYTOF
40%
Loosely correlated
+1.50%
SPHDF - CYTOF
35%
Loosely correlated
N/A
VTVT - CYTOF
29%
Poorly correlated
+9.38%
VERU - CYTOF
28%
Poorly correlated
+6.17%
More

SPHDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPHDF has been loosely correlated with COGT. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPHDF jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHDF
1D Price
Change %
SPHDF100%
N/A
COGT - SPHDF
63%
Loosely correlated
+1.50%
MEOBF - SPHDF
50%
Loosely correlated
N/A
KROS - SPHDF
38%
Loosely correlated
+3.28%
CYTOF - SPHDF
35%
Loosely correlated
N/A
XFOR - SPHDF
34%
Loosely correlated
-0.77%
More